Busto Martín Luis, Carral Freire Maria, Hermida Teresa, Aller Marcos, Busto Castañón Luis
Urology Department, General Surgery Department, Complexo Hospitalario Universitario de A Coruña. A Coruña. Spain.
Arch Esp Urol. 2014 Oct;67(8):699-704.
To report two cases of prostate sarcoma and perform a review of the published literature.
METHODS / RESULTS: The first case is a 21 year old patient who presented acute urine retention and lung metastases on diagnosis. He was diagnosed by TURP of rhabdomyosarcoma of the prostate dying 1 month after surgery. The second case was a 33 years old male who presented to the emergency room with anal pain, urinary symptoms, hematochezia and loss of 20 kg over the past 3 months. Abdominal CT scan showed an 11 x 10 x 9 cm mass in the lower pelvis that infiltrated the bladder and rectum, being unable to define its origin. CA 19.9, CEA and PSA were normal. The suspected diagnosis was a prostate sarcoma infiltrating rectum and bladder. A pelvic exenteration was performed with a wet colostomy. The pathologic diagnosis was a high grade sarcoma not clearly identified of the prostate. He was treated with adriamycin as adjuvant chemotherapy, having local recurrence, nodal involvement and multiple pulmonary metastases after 3 months of follow up
Prostate sarcomas are rare tumors. This makes difficult to know their natural history. Their rapid progression and systemic spread, despite multimodal treatment, gives a mean survival of 24 months. Main survival factors are grade, a complete resection of the tumor and a low local stage. There is a need to find new chemotherapy protocols to increase survival rates as it has been shown in extremities sarcomas.
报告两例前列腺肉瘤病例并对已发表的文献进行综述。
方法/结果:第一例患者为21岁男性,诊断时出现急性尿潴留和肺转移。经经尿道前列腺切除术诊断为前列腺横纹肌肉瘤,术后1个月死亡。第二例患者为33岁男性,因肛门疼痛、泌尿系统症状、便血及在过去3个月内体重减轻20kg就诊于急诊室。腹部CT扫描显示盆腔下部有一个11×10×9cm的肿块,侵犯膀胱和直肠,无法确定其起源。CA 19.9、癌胚抗原(CEA)和前列腺特异性抗原(PSA)均正常。疑似诊断为浸润直肠和膀胱的前列腺肉瘤。行盆腔脏器清除术并进行湿性结肠造口术。病理诊断为前列腺来源不明的高级别肉瘤。给予阿霉素辅助化疗,随访3个月后出现局部复发、淋巴结受累及多发肺转移。
前列腺肉瘤是罕见肿瘤。这使得了解其自然病史变得困难。尽管采取了多模式治疗,但其快速进展和全身扩散导致平均生存期为24个月。主要生存因素包括肿瘤分级、肿瘤完整切除及低局部分期。如在肢体肉瘤中所示,需要寻找新的化疗方案以提高生存率。